LRMR - Income Statement - Larimar Therapeutics, Inc.

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017	Dec-2016	Dec-2015	Dec-2014	Dec-2013	Dec-2012	Dec-2011
REVENUE
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GROSS PROFIT
Cost Of Revenue	0	0.3	0.3	0.3	0.2	78 K	0.3	0.2	0.2	70 K	0	12 K	11 K	4 K
Gross Profit	0	(0.3)	(0.3)	(0.3)	(0.2)	78 K	(0.3)	(0.2)	(0.2)	70 K	0	12 K	11 K	4 K
OPERATING INCOME
Operating Expenses	90.9	41.8	36.5	50.5	42.8	23.2	62.5	53.7	56.9	73.7	35.5	13.8	13.8	13.2
Selling, General and Administrative Expenses	17.6	14.1	12.3	12.1	11.4	2.4	12.9	11.9	17.1	19.1	8.1	4.2	2.2	1.7
Research and Development Expenses	73.0	27.4	24.2	38.4	31.4	20.8	49.5	41.7	39.8	54.6	27.4	9.6	11.5	11.4
Operating Income	(90.9)	(41.8)	(36.5)	(50.5)	(42.8)	(23.2)	(62.7)	(53.9)	(57.1)	(73.8)	(35.5)	(13.8)	(13.8)	(13.2)
PRE-TAX INCOME
Interest Income Expense	0	0	0	0	0	--	0	1.0	0.3	0.8	(0.9)	0	97 K	0
Total Other Income	10.3	4.8	1.2	(0.2)	0.3	82 K	(0.2)	0.9	(1.1)	(0.5)	(1.0)	(0.2)	89 K	3 K
Pre-Tax Income	(80.6)	(36.9)	(35.4)	(50.6)	(42.5)	(23.1)	(63.0)	(52.9)	(58.2)	(74.3)	(36.6)	(14.0)	(13.9)	(13.2)
NET INCOME
Tax Provision	0	0	(1.2)	(0.3)	(0.2)	93.9 K	(1.6)	(0.9)	(0.3)	(0.9)	0	0	0	0
Net Income	(80.6)	(36.9)	(34.2)	(50.3)	(42.3)	(23.1)	(61.4)	(52.0)	(57.9)	(74.3)	(36.6)	(14.0)	(13.9)	(13.2)
EPS	1.32	0.84	1.33	2.93	3.56	2.51	22.9	22.8	25.4	33.3	15.1	6.54	6.4	6.07

Free